Literature DB >> 16004862

Treatment of heart failure with a normal ejection fraction.

Shyam Bhakta1, Mark E Dunlap.   

Abstract

Treatment of diastolic heart failure is divided into acute and chronic management. During acute management, the focus should be treatment of the presenting syndrome, including correction of volume overload, treating hypertension, alleviating ischemia, and controlling tachyarrhythmias. Therefore, acute treatment should include several components: treating volume overload with sodium restriction and diuretics; treating ischemic heart disease with antiplatelet therapy, anticoagulants, and beta blockers; treating hypertension aggressively, using multiple agents if necessary; and treating atrial tachyarrhythmias such as atrial fibrillation with rate-controlling agents, such as beta blockers and possibly nondihydropyridine calcium channel blockers such as diltiazem and verapamil. Antiarrhythmic agents with or without electrical cardioversion may be necessary. Thoroughly evaluate and manage extracardiac precipitants such as anemia and renal failure. Chronic management should also focus on precipitating factors, for which adequate control of hypertension is paramount. Patient education regarding dietary and medication compliance and lifestyle changes is also important. If ischemic heart disease is present, aggressive anti-ischemic therapy is necessary, including revascularization when indicated.

Entities:  

Year:  2005        PMID: 16004862     DOI: 10.1007/s11936-005-0042-y

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  19 in total

Review 1.  beta-Blocker therapy in heart failure: scientific review.

Authors:  JoAnne Micale Foody; Michael H Farrell; Harlan M Krumholz
Journal:  JAMA       Date:  2002-02-20       Impact factor: 56.272

2.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 3.  Clinical practice. Diastolic heart failure.

Authors:  Gerard P Aurigemma; William H Gaasch
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

4.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).

Authors:  S A Hunt; D W Baker; M H Chin; M P Cinquegrani; A M Feldman; G S Francis; T G Ganiats; S Goldstein; G Gregoratos; M L Jessup; R J Noble; M Packer; M A Silver; L W Stevenson; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; A K Jacobs; L F Hiratzka; R O Russell; S C Smith
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

5.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

6.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Authors:  Henry Krum; Ellen B Roecker; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Andrew J S Coats; Hugo A Katus; Michael B Fowler; Milton Packer
Journal:  JAMA       Date:  2003-02-12       Impact factor: 56.272

7.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

8.  Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).

Authors:  A Bergström; B Andersson; M Edner; E Nylander; H Persson; U Dahlström
Journal:  Eur J Heart Fail       Date:  2004-06       Impact factor: 15.534

Review 9.  Left ventricular diastolic dysfunction and diastolic heart failure.

Authors:  William H Gaasch; Michael R Zile
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.